Ajinomoto Co., Inc.
15-1 Kyobashi 1-chome, Chuo-ku
Tokyo
104-8315
Tel: 81-3-5250-8134
Fax: 81-3-5250-8352
Website: http://www.ajinomoto.co.jp/
25 articles about Ajinomoto Co., Inc.
-
Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios
2/13/2024
Ajinomoto Co., Inc., the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on "AminoScience," has expanded its corporate venture capital arm with new U.S. headquarters to grow its investments in U.S. and global companies.
-
The Japanese biotechnology and food company has bought into the gene therapy space with its $620 million acquisition of Ohio-based CDMO and clinical-stage biotech Forge Biologics.
-
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
11/13/2023
Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.
-
Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines
3/26/2021
Bright Peak Therapeutics Inc., a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease, and Ajinomoto Co., Inc. ("Ajinomoto Co."), a leading technology provider for biopharmaceuticals and the owner of Ajinomoto Bio-Pharma Services offering pharmaceutical contract development and manufacturing services, today announced a research collaboration and exclusive license agreement to incorporate AJICA
-
New Ajinomoto Campaign Challenges Assumptions About Monosodium Glutamate (MSG)
12/2/2020
The company joins forces with Pepper Teigen, designer Zipeng Zhu, and Asian food brand Omsom to replace outdated "No MSG" signs with new "KNOW MSG" symbol
-
Cambrooke Therapeutics, Inc. Becomes Ajinomoto Cambrooke, Inc.
4/2/2019
Cambrooke Therapeutics, Inc. announced it has changed its corporate name to Ajinomoto Cambrooke, Inc. effective April 1, 2019.
-
Ajinomoto Acquires Cambrooke Therapeutics
11/10/2017
With this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise, as well as proven flavor and texture-enhancing R&D capabilities.
-
Ajinomoto Appoints Dr. Lori Mcdonald As Vice President Of Compliance
4/6/2017
-
Ajinomoto Brings Pharmaceutical-grade Fermented Amino Acid L-cystine To The North American Market
2/16/2017
-
Filament Biosolutions Announces Strategic Partnership With Ajinomoto To Develop A Portfolio Of Evidence-Based Medical Foods
1/11/2016
-
Albireo Announces The Initiation In Japan Of A Phase III Clinical Trial Of Elobixibat In Chronic Constipation By Ajinomoto
11/10/2015
-
Ajinomoto Althea, Inc. Receives European GMP Certification
9/3/2014
-
Ajinomoto’s North Carolina Plant Receives ISO 9001 Certification
5/6/2013
-
Ajinomoto Completes Acquisition of Althea Technologies, Inc.
4/5/2013
-
Ajinomoto Agrees to Acquire Althea Technologies, Inc. for $175 Million
3/6/2013
-
Global Pharmaceutical Company Licenses Ajinomoto's Corynex Recombinant Protein Expression System Following Successful Proof-of-Concept
3/5/2013
-
Ajinomoto To Exhibit at PepTalk 2012
1/4/2012
-
Ajinomoto Announces New Amino Acid Pricing Structure
11/4/2011
-
Ajinomoto Harnesses Amino Acid Power to Improve Sleep
5/31/2011
-
Chilli Could be Next on the Menu to Fight Flab, Ajinomoto Reveals
3/7/2011